Lerach Coughlin Stoia Geller Rudman & Robbins LLP Files Class Action Suit against Barrier Therapeutics, Inc.

If you wish to serve as lead plaintiff, you must move the Court nolater than 60 days from today. If you wish to discuss this action orhave any questions concerning this notice or your rights or interests,please contact plaintiff's counsel, Samuel H. Rudman or David A.Rosenfeld of Lerach Coughlin at 800/449-4900 or 619/231-1058 or viae-mail at wsl@lerachlaw.com. If you are a member of this class, youcan view a copy of the complaint as filed or join this class actiononline at http://www.lerachlaw.com/cases/barrier/. Any member of thepurported class may move the Court to serve as lead plaintiff throughcounsel of their choice, or may choose to do nothing and remain anabsent class member.

The complaint charges Barrier and certain of its officers anddirectors with violations of the Securities Act of 1933 and SecuritiesExchange Act of 1934. Barrier is a biopharmaceutical company, engagedin the discovery, development, and commercialization of pharmaceuticalproducts in the field of dermatology. The complaint alleges thatBarrier made a series of materially false and misleading statementsconcerning the Company's business and products under development. Inparticular, the Complaint alleges that these statements werematerially false and misleading because they failed to disclose andmisrepresented the following adverse facts: (i) that the Company hadfailed to perform its clinical trials in conformity with FDAguidelines as they had failed to disclose that they had secretlysubstituted the petroleum base within Zimycan, the effect of which wasto substantially lessen the likelihood that the drug could achieve FDAapproval; (ii) that Hyphanox did not have a better safety or efficacyprofile than fluconazole/Diflucan and, in fact, as investorsultimately learned, Hyphanox was significantly less effective thanfluconazole/Diflucan; and (iii) as a result of the foregoing,defendants lacked any reasonable basis for their positive statementsabout Barrier.

On June 29, 2005, Barrier shocked the market when it announced,among other adverse facts, that the Company's drug trials failed todemonstrate that Hyphanox worked as well as fluconazole. In responseto this announcement, the price of Barrier stock plummeted over $6.75per share - - a decline of over 45% - - to below $8.00 per share onextremely heavy trading volume.

Plaintiff seeks to recover damages on behalf of all purchasers ofBarrier common stock during the Class Period . The plaintiff isrepresented by, among other firms, Lerach Coughlin, which hasexpertise in prosecuting investor class actions and extensiveexperience in actions involving financial fraud.

Lerach Coughlin, a 150-lawyer firm with offices in San Diego, SanFrancisco, Los Angeles, New York, Boca Raton, Washington, D.C.,Houston, Philadelphia and Seattle, is active in major litigationspending in federal and state courts throughout the United States andhas taken a leading role in many important actions on behalf ofdefrauded investors, consumers, and companies, as well as victims ofhuman rights violations. Lerach Coughlin lawyers have been responsiblefor more than $20 billion in aggregate recoveries. The Lerach CoughlinWeb site (http://www.lerachlaw.com) has more information about thefirm.